Assessing the protective efficacy of antibodies to the HIV gp41 region by active vaccination

Assessing the protective efficacy of antibodies to the HIV gp41 region by active vaccination

Bibliographic Details
Main Authors:	Sharma SK, Pokorski J, Finn MG, Jacqueline J, Rakasz E, Burton D, Wyatt R
Format:	Article
Language:	English
Published:	BMC 2012-09-01
Series:	Retrovirology

Similar Items

Neutralizing Antibodies Targeting HIV-1 gp41
by: Christophe Caillat, et al.
Published: (2020-10-01)

HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
by: Laurent Verkoczy, et al.
Published: (2014-05-01)

Identification of HIV gp41-specific antibodies that mediate killing of infected cells.
by: Katherine L Williams, et al.
Published: (2019-02-01)

Structure of HIV-1 gp41 with its membrane anchors targeted by neutralizing antibodies
by: Christophe Caillat, et al.
Published: (2021-04-01)

Lipid Binding: A Necessary Evil for Broadly Neutralizing Anti-gp41 Antibodies?
by: Scherer, E, et al.
Published: (2008)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
by: Han D, et al.
Published: (2012-09-01)

Diversification of specificity after maturation of the antibody response to the HIV gp41 epitope ELDKWA.
by: Henry N White, et al.
Published: (2012-01-01)

Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines
by: Koshlan Mayer-Blackwell, et al.
Published: (2022-10-01)

Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.
by: Constantinos Kurt Wibmer, et al.
Published: (2017-01-01)

Analysis of gp41 epitopes in model viral membranes to study HIV-1 neutralization
by: Reichart T, et al.
Published: (2012-09-01)

Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes
by: Nika M. Strokappe, et al.
Published: (2019-06-01)

DNA vaccines that express the MPER of HIV-1 gp41 elicit different antibodies depending upon their transmembrane and cytoplasmic domains
by: Scott JK, et al.
Published: (2012-09-01)

Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.
by: Ling Ye, et al.
Published: (2011-01-01)

Identification of a HIV Gp41-Specific Human Monoclonal Antibody With Potent Antibody-Dependent Cellular Cytotoxicity
by: Zheng Yang, et al.
Published: (2018-11-01)

Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.
by: Mei-Yun Zhang, et al.
Published: (2012-01-01)

Feeding Eggs from Hens Immunized with Specific KLH-Conjugated HIV Peptide Candidate Vaccines to Chicks Induces Specific Anti-HIV gp120 and gp41 Antibodies that Neutralize the Original HIV Antigens
by: Justiz Vaillant, et al.
Published: (2020-12-01)

Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
by: Javier Guenaga, et al.
Published: (2012-01-01)

Soluble and bacteriophage T4 displayed gp41 mutant proteins as HIV-1 vaccine candidates
by: Gao G, et al.
Published: (2012-09-01)

Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization.
by: Arthur S Kim, et al.
Published: (2014-07-01)

Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein.
by: Vinita R Joshi, et al.
Published: (2020-05-01)

Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41.
by: S Moses Dennison, et al.
Published: (2011-01-01)

Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles
by: Sonu Kumar, et al.
Published: (2021-06-01)

Conformational plasticity of the HIV-1 gp41 immunodominant region is recognized by multiple non-neutralizing antibodies
by: Jonathan D. Cook, et al.
Published: (2022-03-01)

SOLUBLE CD4 BINDING TO HIV-1 VIRIONS CAUSES GP120 TO DISSOCIATE FROM GP41
by: Moore, J, et al.
Published: (1991)

Cross-reactive Anti-gp41 HIV-1 Neutralizing Human Monoclonal Antibodies Selected by Competitive Panning Against gp140 – an Update
by: Sidorov Igor, et al.
Published: (2005-12-01)

Development of HIV-1 fusion inhibitors targeting gp41
by: Lu, K., et al.
Published: (2014)

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection
by: Xinling Wang, et al.
Published: (2021-03-01)

Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.
by: Ben-Jiang Ma, et al.
Published: (2011-09-01)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
by: Seth H. Pincus, et al.
Published: (2021-07-01)

The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects
by: Huan Liu, et al.
Published: (2018-04-01)

HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies.
by: Ji Wang, et al.
Published: (2011-03-01)

Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection
by: Naveen K. Vaidya, et al.
Published: (2018-06-01)

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41
by: Caffrey Michael, et al.
Published: (2004-03-01)

Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.
by: Sattentau, Q, et al.
Published: (1995)

Binding of HIV-1 gp41-directed neutralizing and non-neutralizing fragment antibody binding domain (Fab) and single chain variable fragment (ScFv) antibodies to the ectodomain of gp41 in the pre-hairpin and six-helix bundle conformations.
by: John M Louis, et al.
Published: (2014-01-01)

Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design.
by: Serrano, S, et al.
Published: (2014)

Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer.
by: Mukta D Khasnis, et al.
Published: (2016-12-01)

P09-13. Structure of HIV-1 gp41 interactive region: layered architecture and basis of conformational mobility
by: Sodroski J, et al.
Published: (2009-10-01)

Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1
by: Jing Pu, et al.
Published: (2021-01-01)

The Gp41 Sequence Connecting Mper and Tm Domains Constitutes a Distinct HIV-1 "Fusion Peptide" Targeted by Neutralizing Antibodies
by: Apellaniz, B, et al.
Published: (2014)